Skip to main content
Skip to main content
NVO logo

Novo Nordisk A/S (NVO)

For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Novo Nordisk A/S (NVO) operates in the Healthcare sector, last quoted at $36.67 with a 163B market capitalization. The stock scores 51/100, a moderate rating based on 9 quantitative KPIs.

Last analyzed: 2026年3月15日
51/100 AI Score Target $53.40 (+45.6%) MCap 163B Vol 12M

Novo Nordisk A/S (NVO) Healthcare & Pipeline Overview

CEOMaziar Mike Doustdar
Employees77406
HeadquartersBagsvaerd, DK
IPO Year1981

Novo Nordisk A/S is a leading global healthcare company specializing in diabetes and obesity care, alongside treatments for rare diseases. With a high profit margin and substantial market capitalization, the company distinguishes itself through innovative drug development and strategic collaborations, operating across Europe, North America, and Asia.

Data Provenance | Financial Data Quantitative Analysis NASDAQ Analysis: 2026年3月15日

Investment Thesis

Novo Nordisk A/S presents a compelling investment case driven by its dominance in the diabetes and obesity care market, reflected in its high gross margin of 81.0% and a profit margin of 33.1%. The company's focus on innovative treatments and strategic collaborations positions it for sustained growth. Key value drivers include the increasing global prevalence of diabetes and obesity, which fuels demand for Novo Nordisk's products. Upcoming catalysts include the potential approval and launch of new drugs in the cardiometabolic space developed through its collaboration with Valo Health, Inc. Potential risks include increasing competition from biosimilars and potential regulatory challenges. The company's dividend yield of 4.72% offers an attractive return for investors.

Based on FMP financials and quantitative analysis

Key Highlights

  • Market capitalization of $168.70 billion, reflecting its significant presence in the pharmaceutical industry.
  • Profit margin of 33.1%, indicating strong profitability and efficient operations.
  • Gross margin of 81.0%, showcasing the company's ability to maintain high pricing and manage costs effectively.
  • Dividend yield of 4.72%, providing a substantial return for investors.
  • Beta of 0.27, suggesting lower volatility compared to the overall market.

Competitors & Peers

Strengths

  • Strong market position in diabetes and obesity care.
  • High profit and gross margins.
  • Extensive global distribution network.
  • Innovative product portfolio.

Weaknesses

  • Reliance on a limited number of key products.
  • Exposure to patent expiration risks.
  • Potential for biosimilar competition.
  • Currency exchange rate fluctuations.

Catalysts

  • Continued expansion of GLP-1 receptor agonist market share.
  • Potential FDA approval of new drugs in the cardiometabolic space from the Valo Health collaboration.
  • Strategic partnerships to expand product offerings and market reach.
  • Publication of clinical trial results for new diabetes and obesity treatments.

Risks

  • Increasing competition from biosimilars.
  • Regulatory changes and pricing pressures.
  • Currency exchange rate fluctuations.
  • Product liability lawsuits.
  • Dependence on key products in the diabetes and obesity care segments.

Growth Opportunities

  • Expanding Obesity Care Market: The global obesity care market is projected to reach $37.3 billion by 2027, driven by increasing obesity rates worldwide. Novo Nordisk is well-positioned to capitalize on this growth through its existing portfolio of obesity treatments and ongoing research into new therapies. The company's collaboration with UNICEF to tackle childhood obesity also provides a unique opportunity to address the issue at its roots.
  • Diabetes Treatment Innovation: The diabetes treatment market is expected to grow to $58.4 billion by 2025. Novo Nordisk's focus on developing innovative insulin pens, smart solutions, and GLP-1 receptor agonists positions it to capture a significant share of this market. The company's Dose Check application and smart insulin pens enhance patient adherence and improve treatment outcomes.
  • Rare Disease Segment Expansion: The rare disease treatment market is characterized by high unmet needs and premium pricing. Novo Nordisk's Rare Disease segment, which includes treatments for rare blood disorders and endocrine disorders, offers significant growth potential. Expanding its portfolio of rare disease treatments through internal research and strategic acquisitions can drive revenue growth.
  • Geographic Expansion in Emerging Markets: Emerging markets, such as China and India, are experiencing rapid growth in diabetes and obesity rates. Novo Nordisk's presence in these markets provides a strong foundation for future growth. Expanding its distribution network and tailoring its product offerings to meet the specific needs of these markets can drive significant revenue gains.
  • Cardiovascular Disease Prevention: Novo Nordisk's focus on cardiovascular disease prevention, particularly in patients with diabetes and obesity, represents a significant growth opportunity. Developing and marketing drugs that address both diabetes and cardiovascular risk factors can create a synergistic effect and drive adoption. The collaboration with Valo Health, Inc. aims to discover and develop novel drug programs in this space.

Opportunities

  • Expanding into emerging markets.
  • Developing new treatments for related conditions, such as cardiovascular disease.
  • Acquiring or partnering with other pharmaceutical companies.
  • Leveraging digital health technologies to improve patient outcomes.

Threats

  • Increasing competition from other pharmaceutical companies.
  • Regulatory changes and pricing pressures.
  • Product liability lawsuits.
  • Economic downturns.

Competitive Advantages

  • Strong brand reputation in diabetes care.
  • Extensive portfolio of patented drugs.
  • Global distribution network.
  • High barriers to entry in the pharmaceutical industry due to regulatory requirements and R&D costs.

About NVO

Founded in 1923 and headquartered in Bagsvaerd, Denmark, Novo Nordisk A/S has evolved into a global pharmaceutical giant. The company is dedicated to discovering, developing, manufacturing, and marketing pharmaceutical products, primarily focusing on diabetes and obesity care. Its operations are divided into two main segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment provides a range of products for diabetes management, obesity treatment, and cardiovascular disease prevention. This includes insulin pens, oral antidiabetic drugs, and GLP-1 receptor agonists. The Rare Disease segment focuses on treatments for rare blood disorders, rare endocrine disorders, and hormone replacement therapy. Novo Nordisk distributes its products across Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, and North America. The company also emphasizes innovative solutions, such as smart insulin pens and the Dose Check application, to enhance diabetes treatment. Strategic collaborations, including partnerships with UNICEF to tackle childhood obesity and Valo Health, Inc. for cardiometabolic drug discovery, underscore Novo Nordisk’s commitment to addressing global health challenges.

What They Do

  • Researches and develops pharmaceutical products.
  • Manufactures and distributes pharmaceutical products globally.
  • Specializes in diabetes and obesity care.
  • Offers treatments for rare blood disorders.
  • Provides hormone replacement therapy.
  • Develops innovative insulin pens and injection needles.
  • Creates smart solutions for diabetes treatment, such as Dose Check.

Business Model

  • Develops and patents pharmaceutical products.
  • Manufactures drugs in-house and through contract manufacturers.
  • Distributes products through a global network of distributors and sales representatives.
  • Generates revenue through the sale of prescription drugs.

Industry Context

Novo Nordisk operates in the global pharmaceutical industry, specifically within the diabetes, obesity care, and rare disease segments. The market for diabetes and obesity treatments is expanding due to rising global prevalence rates. The company faces competition from major pharmaceutical companies such as Abbott Laboratories (ABT), Amgen (AMGN), AstraZeneca (AZN), Gilead Sciences (GILD), and GSK (GSK). Novo Nordisk's focus on innovation and strategic partnerships allows it to maintain a competitive edge in this dynamic market.

Key Customers

  • Patients with diabetes.
  • Patients with obesity.
  • Patients with rare blood disorders.
  • Patients with rare endocrine disorders.
  • Healthcare providers and hospitals.
AI Confidence: 73% Updated: 2026年3月15日

Financials

Chart & Info

Novo Nordisk A/S (NVO) stock price: $36.67 (-0.31, -0.84%)

Latest News

Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NVO.

Price Targets

Consensus target: $53.40

MoonshotScore

51/100

What does this score mean?

The MoonshotScore rates NVO's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Classification

Sector Healthcare Industry Drug Manufacturers - General

Competitors & Peers

Latest News

Latest Novo Nordisk A/S Analysis

Leadership: Maziar Mike Doustdar

Executive Vice President and Head of International Operations

Maziar Mike Doustdar serves as Executive Vice President and Head of International Operations at Novo Nordisk. His career spans various leadership roles within the pharmaceutical industry, demonstrating expertise in global market strategy and operational management. He has extensive experience in driving commercial success and expanding market presence in international regions. His leadership is focused on innovation and patient-centric solutions.

Track Record: Under his leadership, Novo Nordisk has expanded its international operations and strengthened its presence in key emerging markets. He has overseen the successful launch of several key products and implemented strategies to improve market access and patient outcomes. His focus on innovation and strategic partnerships has contributed to the company's growth and competitive advantage.

Novo Nordisk A/S ADR Information

An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company that are held by a U.S. depositary bank. NVO, as an ADR, allows U.S. investors to easily invest in Novo Nordisk A/S without the complexities of cross-border transactions. The depositary bank handles currency conversions and other administrative tasks.

  • Home Market Ticker: Copenhagen Stock Exchange (Nasdaq Copenhagen), Denmark
Currency Risk: As an ADR, NVO is subject to currency risk. The value of the ADR can fluctuate based on changes in the exchange rate between the U.S. dollar and the Danish Krone. If the Krone weakens against the dollar, the value of the ADR may decrease, even if the underlying shares in Denmark remain stable.
Tax Implications: U.S. investors in NVO ADRs may be subject to foreign dividend withholding taxes imposed by the Danish government. The standard withholding tax rate is 27%. However, this may be reduced under the tax treaty between the United States and Denmark. Investors can typically claim a foreign tax credit on their U.S. tax return for the amount of foreign taxes withheld.
Trading Hours: The Copenhagen Stock Exchange (Nasdaq Copenhagen) operates from 09:00 to 17:00 Central European Time (CET). This is 3:00 AM to 11:00 AM Eastern Time (ET). Therefore, there is a significant overlap between trading hours in Copenhagen and the U.S. pre-market trading session. However, U.S. investors should be aware of the time difference when monitoring news and announcements from the company.

What Investors Ask About Novo Nordisk A/S (NVO)

What are the key factors to evaluate for NVO?

Novo Nordisk A/S (NVO) currently holds an AI score of 51/100, indicating moderate score. The stock trades at a P/E of 10.3x, below the S&P 500 average (~20-25x), potentially signaling value. Analysts target $53.40 (+46% from $36.67). Key strength: Strong market position in diabetes and obesity care. Primary risk to monitor: Increasing competition from biosimilars. This is not financial advice.

How frequently does NVO data refresh on this page?

NVO prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.

What has driven NVO's recent stock price performance?

Recent price movement in Novo Nordisk A/S (NVO) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. The current analyst target of $53.40 implies 46% upside from here. Notable catalyst: Strong market position in diabetes and obesity care. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.

Should investors consider NVO overvalued or undervalued right now?

Determining whether Novo Nordisk A/S (NVO) is overvalued or undervalued requires examining multiple metrics. Its P/E ratio is 10.3. Analysts target $53.40 (+46% from current price), suggesting analysts see upside potential. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.

What research should beginners do before buying NVO?

Before investing in Novo Nordisk A/S (NVO), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Why might investors consider adding NVO to a portfolio?

Potential reasons to consider Novo Nordisk A/S (NVO) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Strong market position in diabetes and obesity care. Additionally: High profit and gross margins. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.

Can I buy fractional shares of NVO?

Yes, most major brokerages offer fractional shares of Novo Nordisk A/S (NVO) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.

How can I track NVO's earnings and financial reports?

Novo Nordisk A/S (NVO) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for NVO earnings announcements is recommended.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Analysis updated AI Score refreshed daily
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .

Data provided for informational purposes only.

Analysis Notes
  • Information is based on available data and may be subject to change.
  • Financial metrics are as of the latest available reporting period.
Data Sources

Popular Stocks